Zilong Qiu, a neuroscientist who served as the lead researcher for an experimental gene-editing trial, has been fired by his institution following a government probe. The dismissal comes after it was revealed that Qiu concealed the death of a six-year-old girl who participated in the study. State media in China reported the decision on Friday, citing a statement from local authorities in Shanghai.
The girl died last year after receiving experimental gene therapy intended to correct a rare neurodevelopmental condition known as Snijders Blok-Campeau syndrome. According to a joint investigation conducted by Science and Retraction Watch, the condition was not considered life-threatening, and the nature of the illness was not disclosed in the published research. The study was approved by the hospital's ethics committee in January 2025, but the committee terminated the trial in March after the child died from complications associated with the therapy.
Qiu was removed from his position as deputy director of the Songjiang Research Institute, which is affiliated with Shanghai Jiao Tong University. The authorities stated that he was given a five-year suspension from participating in scientific projects. Additionally, his name was recorded in a database for serious breaches of research integrity. Another researcher on Qiu's team was also fired and suspended for five years, while several other individuals with ties to the hospital were punished.
The Nature journal published a paper detailing the trial on February 18. However, the investigation found that Qiu made no mention of the girl's participation or her subsequent death in the publication. The July report noted that the hospital allowed the experimental treatment to proceed under a specific regulatory provision that did not require approval from national regulators. After the child's death, the hospital paid a modest fine to a local health authority, but Qiu was not publicly sanctioned at that time.
Shanghai authorities determined that Qiu's team failed to properly inform the hospital of potential safety issues identified in earlier tests conducted on primates. The girl's parents, who funded the experiment with more than $800,000, were not adequately informed about the risks involved. The father of the deceased child told Science that learning about the missing safeguards had fundamentally changed his view of the project. He described many of the arrangements as unusual and dangerous.
This scandal represents a significant setback for China's ambitions to rival the United States as a leading biotech power. The incident echoes a previous controversy in 2018 involving a biophysicist who secretly produced gene-edited babies. That scientist was later sentenced to three years in prison. AFP has reached out to Qiu for comment regarding his dismissal.
The case highlights ongoing concerns about transparency and ethical oversight in China's rapidly expanding biotechnology sector. The failure to disclose the child's death in a high-profile journal has intensified scrutiny on how experimental therapies are monitored and reported. Regulators are now expected to review similar provisions that allow trials to proceed without national approval to prevent future incidents.
The investigation also shed light on the financial aspects of the trial, noting that the parents bore the significant cost of the experiment. Despite the substantial investment, the family felt the process lacked necessary safeguards. The punishment of multiple team members suggests a broader review of the research group's practices and the hospital's role in overseeing the trial.
State broadcaster CCTV reported the details of the dismissal, referencing the specific study published in Nature. The official statement identified Qiu by his surname and outlined the penalties imposed on the research team. The decision underscores the Chinese government's commitment to enforcing research integrity in its scientific community.
Following the 2018 gene-edited babies scandal, Chinese authorities have taken steps to strengthen regulations in the field. The recent firing of Qiu and the suspension of other researchers indicate that these efforts are being applied to individual cases of misconduct. The outcome of this probe may influence how future gene-editing trials are approved and monitored in the country.







